A phase 1a study of at-527, a novel pan-genotypic purine nucleotide prodrug inhibitor of hepatitis c virus (HCV)

Authors
Category Primary study
ConferenceHepatology
Year 2017
This article has no abstract
Epistemonikos ID: 47a548ac20c15d4b1de61b7c4bbbd31fa7c36ba4
First added on: Apr 29, 2026